Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance.
作者信息
Kristinsson Sigurdur Y, Goldin Lynn R, Björkholm Magnus, Turesson Ingemar, Landgren Ola
出版信息
Haematologica. 2009 Aug;94(8):1179-81. doi: 10.3324/haematol.2009.006346. Epub 2009 Jun 22.
Abstract
摘要
相似文献
1
Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance.
Haematologica. 2009 Aug;94(8):1179-81. doi: 10.3324/haematol.2009.006346. Epub 2009 Jun 22.
2
Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden.
Int J Cancer. 2009 Nov 1;125(9):2147-50. doi: 10.1002/ijc.24514.
3
Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study.
Int J Cancer. 2006 Jun 15;118(12):3095-8. doi: 10.1002/ijc.21745.
4
Familiality of benign and malignant paraproteinemias. A population-based cancer-registry study of multiple myeloma families.
Haematologica. 2005 Jan;90(1):66-71.
5
[Malignant transformation of monoclonal gammopathy of undetermined significance].
Presse Med. 2007 Dec;36(12 Pt 3):1985-96. doi: 10.1016/j.lpm.2007.01.040. Epub 2007 May 16.
6
Genetic predisposition for monoclonal gammopathy of undetermined significance.
Mayo Clin Proc. 2008 May;83(5):601-2; author reply 602-3. doi: 10.4065/83.5.601-a.
7
Familial monoclonal gammopathy: hyper-responsive B cells in unaffected family members.
Eur J Haematol. 2011 May;86(5):396-404. doi: 10.1111/j.1600-0609.2011.01593.x. Epub 2011 Mar 30.
8
Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
Haematologica. 2009 Dec;94(12):1708-13. doi: 10.3324/haematol.2009.011064.
9
The BRAF-V600E mutation in hematological malignancies: a new player in hairy cell leukemia and Langerhans cell histiocytosis.
Leuk Lymphoma. 2012 Dec;53(12):2339-40. doi: 10.3109/10428194.2012.706289. Epub 2012 Aug 13.
10
Novel aspects pertaining to the relationship of Waldenström's macroglobulinemia, IgM monoclonal gammopathy of undetermined significance, polyclonal gammopathy, and hypoglobulinemia.
Clin Lymphoma Myeloma. 2009 Mar;9(1):19-22. doi: 10.3816/CLM.2009.n.003.
引用本文的文献
1
Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study.
Sci Rep. 2021 Sep 29;11(1):19266. doi: 10.1038/s41598-021-98803-1.
2
Epidemiology, genetics and treatment of multiple myeloma and precursor diseases.
Int J Cancer. 2021 Dec 15;149(12):1980-1996. doi: 10.1002/ijc.33762. Epub 2021 Aug 30.
3
Parental longevity and survival among patients with multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study.
Br J Haematol. 2019 Jul;186(1):37-44. doi: 10.1111/bjh.15883. Epub 2019 Mar 24.
4
Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report.
BMC Cancer. 2017 Nov 6;17(1):718. doi: 10.1186/s12885-017-3715-5.
5
Search for familial clustering of cancer in monoclonal gammopathy of unknown significance.
Blood Cancer J. 2016 Jul 8;6(7):e445. doi: 10.1038/bcj.2016.58.
6
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.
Haematologica. 2014 Jun;99(6):984-96. doi: 10.3324/haematol.2013.100552. Epub 2014 Mar 21.
7
Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics.
Blood. 2012 Jun 7;119(23):5359-66. doi: 10.1182/blood-2011-11-387324. Epub 2012 Feb 21.
8
Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies.
Haematologica. 2009 Nov;94(11):1581-9. doi: 10.3324/haematol.2009.008979. Epub 2009 Jul 7.
本文引用的文献
1
Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden.
Blood. 2009 Jul 23;114(4):791-5. doi: 10.1182/blood-2008-12-191676. Epub 2009 Jan 30.
2
Familial myeloma.
N Engl J Med. 2008 Oct 16;359(16):1734-5; author reply 1735. doi: 10.1056/NEJMc081677.
3
Familial myeloma.
N Engl J Med. 2008 Jul 10;359(2):152-7. doi: 10.1056/NEJMoa0708704.
4
Prevalence of monoclonal gammopathy of undetermined significance.
N Engl J Med. 2006 Mar 30;354(13):1362-9. doi: 10.1056/NEJMoa054494.
5
Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study.
Int J Cancer. 2006 Jun 15;118(12):3095-8. doi: 10.1002/ijc.21745.
6
Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: effects of chemotherapy on the monoclonal protein.
Ann Hematol. 2004 Oct;83(10):658-60. doi: 10.1007/s00277-004-0896-1. Epub 2004 Jul 23.
7
Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.
Blood. 2003 Nov 15;102(10):3759-64. doi: 10.1182/blood-2003-03-0801. Epub 2003 Jul 24.
8
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.
Br J Haematol. 2003 Jun;121(5):749-57.
9
A long-term study of prognosis in monoclonal gammopathy of undetermined significance.
N Engl J Med. 2002 Feb 21;346(8):564-9. doi: 10.1056/NEJMoa01133202.
10
Familial bladder cancer in the National Swedish Family Cancer Database.
J Urol. 2001 Dec;166(6):2129-33.
Zotero 插件